Tempo Pharma Secures $12.1 Million

Tempo Pharmaceuticals Inc., a Cambridge, Mass.-based developer of nanoparticle technology to improve drug efficacy, has raised $12.1 million in Series A funding. Venrock and seed backer Polaris Venture Partners co-led the deal, and were joined by Lux Capital.